Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172761944> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W3172761944 endingPage "1070" @default.
- W3172761944 startingPage "1070" @default.
- W3172761944 abstract "1070 Background: In PADA-1 (NCT03079011), a phase III trial testing the clinical utility of ESR1 mut detection, ER+ HER2- advanced breast patients (ABC pts) received Aromatase Inhibitor (AI) and Palbociclib (Pal) +/- LHRH agonist as first line therapy. PADA-1 was open to “AI-sensitive” pts, including those with de novo stage IV disease or metastatic relapse after adjuvant endocrine therapy but also pts with metastatic relapses during adjuvant tamoxifen (TAM). In this subsidiary analysis, we report the efficacy of AI+PAL as first line therapy in patients relapsing on adjuvant TAM. Methods: Main inclusion criteria in PADA-1 are: pre- or post-menopausal pts with ER+ HER2- ABC, who did not receive any prior therapy for ABC and who had no adjuvant AI or completed adjuvant AI for > 12 months or who had disease recurrence while on adjuvant TAM. Results: From 04/2017 to 01/2019, 1017 ABC pts have been included in PADA-1, of which 115 (11.3%) had a metastatic relapse while on adjuvant TAM (TAM only (N = 112) or TAM+GnRH agonist (N = 3)). Median age at inclusion was 46 years (range 25-81), and 58 (50.4%) patients had visceral disease. The median PFS under AI+PAL was 20.4 months (95%CI16.1;27.8) in patients relapsing during adjuvant TAM. In contrast, median PFS in patients with de novo metastatic disease and metastatic relapses after the completion of adjuvant endocrine therapy were 30.6 months (95%CI26.7;Not reached) and 27.8 months (95%CI24.1;30.)], respectively. A subgroup analysis among patients relapsing on adjuvant TAM showed that those relapsing during the first two years of adjuvant TAM had a shorter PFS (11.4 months 95%CI[8.7;20.7]) than those relapsing after 2 years of adjuvant TAM (23.8 months 95%CI[20.2;Not reached]). Conclusions: To our knowledge, these are the first data on first line AI+CDK4/6 inhibitor in patients relapsing on adjuvant TAM. While PFS on AI + PAL appears primarily driven by endocrine resistance status, our data show that AI+PAL is a valuable option also in patients relapsing during adjuvant TAM. Clinical trial information: NCT03079011 ." @default.
- W3172761944 created "2021-06-22" @default.
- W3172761944 creator A5002381363 @default.
- W3172761944 creator A5005286764 @default.
- W3172761944 creator A5009030272 @default.
- W3172761944 creator A5018378577 @default.
- W3172761944 creator A5020889881 @default.
- W3172761944 creator A5027179093 @default.
- W3172761944 creator A5043263795 @default.
- W3172761944 creator A5049751222 @default.
- W3172761944 creator A5050873478 @default.
- W3172761944 creator A5053628635 @default.
- W3172761944 creator A5055313226 @default.
- W3172761944 creator A5057293211 @default.
- W3172761944 creator A5058791215 @default.
- W3172761944 creator A5073011726 @default.
- W3172761944 creator A5083142899 @default.
- W3172761944 creator A5084631227 @default.
- W3172761944 date "2021-05-20" @default.
- W3172761944 modified "2023-10-12" @default.
- W3172761944 title "Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial." @default.
- W3172761944 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.1070" @default.
- W3172761944 hasPublicationYear "2021" @default.
- W3172761944 type Work @default.
- W3172761944 sameAs 3172761944 @default.
- W3172761944 citedByCount "1" @default.
- W3172761944 countsByYear W31727619442022 @default.
- W3172761944 crossrefType "journal-article" @default.
- W3172761944 hasAuthorship W3172761944A5002381363 @default.
- W3172761944 hasAuthorship W3172761944A5005286764 @default.
- W3172761944 hasAuthorship W3172761944A5009030272 @default.
- W3172761944 hasAuthorship W3172761944A5018378577 @default.
- W3172761944 hasAuthorship W3172761944A5020889881 @default.
- W3172761944 hasAuthorship W3172761944A5027179093 @default.
- W3172761944 hasAuthorship W3172761944A5043263795 @default.
- W3172761944 hasAuthorship W3172761944A5049751222 @default.
- W3172761944 hasAuthorship W3172761944A5050873478 @default.
- W3172761944 hasAuthorship W3172761944A5053628635 @default.
- W3172761944 hasAuthorship W3172761944A5055313226 @default.
- W3172761944 hasAuthorship W3172761944A5057293211 @default.
- W3172761944 hasAuthorship W3172761944A5058791215 @default.
- W3172761944 hasAuthorship W3172761944A5073011726 @default.
- W3172761944 hasAuthorship W3172761944A5083142899 @default.
- W3172761944 hasAuthorship W3172761944A5084631227 @default.
- W3172761944 hasConcept C121608353 @default.
- W3172761944 hasConcept C126322002 @default.
- W3172761944 hasConcept C143998085 @default.
- W3172761944 hasConcept C2775930923 @default.
- W3172761944 hasConcept C2777176818 @default.
- W3172761944 hasConcept C2777863537 @default.
- W3172761944 hasConcept C2777982462 @default.
- W3172761944 hasConcept C2778504769 @default.
- W3172761944 hasConcept C2778812593 @default.
- W3172761944 hasConcept C2779744173 @default.
- W3172761944 hasConcept C2780482068 @default.
- W3172761944 hasConcept C29456083 @default.
- W3172761944 hasConcept C530470458 @default.
- W3172761944 hasConcept C71924100 @default.
- W3172761944 hasConceptScore W3172761944C121608353 @default.
- W3172761944 hasConceptScore W3172761944C126322002 @default.
- W3172761944 hasConceptScore W3172761944C143998085 @default.
- W3172761944 hasConceptScore W3172761944C2775930923 @default.
- W3172761944 hasConceptScore W3172761944C2777176818 @default.
- W3172761944 hasConceptScore W3172761944C2777863537 @default.
- W3172761944 hasConceptScore W3172761944C2777982462 @default.
- W3172761944 hasConceptScore W3172761944C2778504769 @default.
- W3172761944 hasConceptScore W3172761944C2778812593 @default.
- W3172761944 hasConceptScore W3172761944C2779744173 @default.
- W3172761944 hasConceptScore W3172761944C2780482068 @default.
- W3172761944 hasConceptScore W3172761944C29456083 @default.
- W3172761944 hasConceptScore W3172761944C530470458 @default.
- W3172761944 hasConceptScore W3172761944C71924100 @default.
- W3172761944 hasFunder F4320307765 @default.
- W3172761944 hasIssue "15_suppl" @default.
- W3172761944 hasLocation W31727619441 @default.
- W3172761944 hasOpenAccess W3172761944 @default.
- W3172761944 hasPrimaryLocation W31727619441 @default.
- W3172761944 hasRelatedWork W2028465294 @default.
- W3172761944 hasRelatedWork W2028501150 @default.
- W3172761944 hasRelatedWork W2040234260 @default.
- W3172761944 hasRelatedWork W2087683876 @default.
- W3172761944 hasRelatedWork W2100085165 @default.
- W3172761944 hasRelatedWork W2144224845 @default.
- W3172761944 hasRelatedWork W2339773972 @default.
- W3172761944 hasRelatedWork W2747078758 @default.
- W3172761944 hasRelatedWork W3172761944 @default.
- W3172761944 hasRelatedWork W4226356606 @default.
- W3172761944 hasVolume "39" @default.
- W3172761944 isParatext "false" @default.
- W3172761944 isRetracted "false" @default.
- W3172761944 magId "3172761944" @default.
- W3172761944 workType "article" @default.